ЕКСПРЕСІЯ мiРНК ЯК ПРОГНОСТИЧНИЙ МАРКЕР ПЕРЕБІГУ НИРКОВО-КЛІТИННОГО РАКУ

• Date: 2023
• Main Authors: Vitruk, Yu., Borikun, T., Rossylna, O., Zadvornyi, T., Semko, S., Voylenko, O., Stakhovsky, O., Shipko, A., Stakhovsky, E.
• Format: Article
• Language: English
• Published: PH Akademperiodyka 2023
• Subjects: мікроРНК; нирково-клітинний рак; ПЛР у реальному часі; прогноз
• Online Access: https://exp-oncology.com.ua/index.php/Exp/article/view/2022-2-6
• Journal Title: Experimental Oncology

Renal cell carcinoma (RCC) is one of the most common solid tumors in adults. There is a lack of reliable prognostic and predictive biomarkers for RCC course. Dysregulation of miRNAs expression has been reported to be involved in RCC progression. However, the data on miRNAs expression patterns in tumors are controversial. Aim: To investigate the expression and clinical significance of miR-99b, -144, -155, -210, -222, -302а, -377 in RCC ex vivo. Materials and Methods: Retrospective analysis of the expression levels of miRNAs -99b, -144, -155, -210, -222, -302а, -377 in tumor tissue of 126 patients with clear cell RCC was performed using quantitative polymerase chain reaction. Results: Overexpression of miR-99b, -222, -302a and low levels of miR-155 in RCC tissues were significantly associated with advanced tumor stage (p < 0.05). In majority of patients with distant metastases (> 60%), high levels of miR-99b and 377 were detected (p < 0.05). High/low miR-99b, -144, -155, -210, -222, and -302a ratio was significantly associated with Fuhrman grade of tumors. Conclusion: Aberrant expression of miR-99b, -144, -155, -210, -222, -302а, -377 is strongly associated with advanced RCC, and panel of these miRNAs may be a useful prognostic marker for RCC course.